A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study

American Heart Journal

Volumn 169, Issue 5, 2015, Pages 597-604.e5

  Lip, Gregory Y H ^a,b   Merino, Jose ^c   Ezekowitz, Michael ^d   Ellenbogen, Kenneth ^e   Zamoryakhin, Dmitry ^f   Lanz, Hans ^g   Jin, James ^g   Al Saadi, Naab ^h   Mercuri, Michele ^g   Goette, Andreas ⁱ  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DAIICHI SANKYO CO   (Japan)

^g DAIICHI SANKYO INC   (United States)

^h Department of Genetic and Molecular Toxicology   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM THROMBOSIS; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ADULT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; METHODOLOGY; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; ELECTRIC COUNTERSHOCK; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PYRIDINES; RESEARCH DESIGN; STROKE; THIAZOLES; THROMBOEMBOLISM; WARFARIN;

EID: 84929273874     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.02.009     Document Type: Article

References (24)

1. R. De Caterina, S. Husted, and L. Wallentin Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Thromb Haemost 110 6 2013 1087 1107
2. D.M. Weinberg, and J. Mancini Anticoagulation for cardioversion of atrial fibrillation Am J Cardiol 63 11 1989 745 746
3. A.L. Klein, R.A. Grimm, and R.D. Murray Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med 344 19 2001 1411 1420
4. J. Wilshire, A. Smith, and A. Bohm Routine unselected access to day case electrical cardioversion of persistent atrial fibrillation: anticoagulant preparation is the key factor Scott Med J 49 1 2004 26 29
5. C.T. Ruff, R.P. Giugliano, and E. Braunwald Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 9921 2014 955 962
6. L. Resnekov, and L. McDonald Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion Br Heart J 29 6 1967 926 936
7. B. Lown, M.G. Perlroth, and S. Kaidbey «Cardioversion» of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients N Engl J Med 269 1963 325 331
8. J.B. Jensen, J.O. Humphries, and W.B. Kouwenhoven Electroshock for atrial flutter and atrial fibrillation. Follow-up studies on 50 patients JAMA 194 11 1965 1181 1184
9. A.Z. Arnold, M.J. Mick, and R.P. Mazurek Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J Am Coll Cardiol 19 4 1992 851 855
10. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE Multicenter Study). Steering and Publications Committees of the ACUTE Study Am J Cardiol 81 7 1998 877 883
11. R. Rokseth Clinical considerations in quinidine therapy of chronic auricular fibrillation. A study of 200 unselected patients - with follow-up Acta Med Scand 174 1963 171 178
12. C.J. Bjerkelund, and O.M. Orning The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation Am J Cardiol 23 2 1969 208 216
13. J.J. Morris Jr., Y. Kong, and W.C. North Experience with "Cardioversion" of atrial fibrillation and flutter Am J Cardiol 14 1964 94 100
14. D. Roy, E. Marchand, and P. Gagne Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation Am Heart J 112 5 1986 1039 1043
15. G. Flaker, R.D. Lopes, and S.M. Al-Khatib Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) J Am Coll Cardiol 63 11 2014 1082 1087
16. E. Moreyra, R.S. Finkelhor, and R.D. Cebul Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials Am Heart J 129 1 1995 71 75
17. R. Nagarakanti, M.D. Ezekowitz, and J. Oldgren Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2 2011 131 136
18. J.P. Piccini, S.R. Stevens, and Y. Lokhnygina Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 19 2013 1998 2006
19. R. Cappato, M.D. Ezekowitz, and A.L. Klein Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation Eur Heart J 35 47 2014 3346 3355
20. G.Y. Lip, and G. Agnelli Edoxaban: a focused review of its clinical pharmacology Eur Heart J 35 28 2014 1844 1855
21. T. Fuji, C.J. Wang, and S. Fujita Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial Thromb Res 134 6 2014 1198 1204
22. G. Raskob, A.T. Cohen, and B.I. Eriksson Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study Thromb Haemost 104 3 2010 642 649
23. R.P. Giugliano, C.T. Ruff, and E. Braunwald Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 22 2013 2093 2104
24. H.R. Buller Edoxaban versus warfarin for venous thromboembolism N Engl J Med 370 1 2014 80 81